NovaBay Pharmaceuticals Inc
NBY5.250USD
+2.300+77.97%
收盘 12/19, 16:00（美东）报价延迟15分钟
31.56M总市值
0.85市盈率 TTM
关于 NovaBay Pharmaceuticals Inc 公司
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc简介
公司代码NBY
公司名称NovaBay Pharmaceuticals Inc
上市日期Oct 26, 2007
CEOKazley (Michael John)
员工数量14
证券类型Ordinary Share
年结日Oct 26
公司地址2000 Powell St Ste 1150
城市EMERYVILLE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编94608-1804
电话15108998800
网址https://novabay.com/
公司代码NBY
上市日期Oct 26, 2007
CEOKazley (Michael John)
NovaBay Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
地区USD
名称
营收
占比
United States
9.78M
100.00%
业务
地区
业务USD
名称
营收
占比
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Poplar Point Capital Management LLC
0.81%
The Vanguard Group, Inc.
0.07%
Geode Capital Management, L.L.C.
0.04%
State Street Investment Management (US)
0.02%
Apollon Wealth Management, LLC
0.02%
其他
99.04%
持股股东
持股股东
占比
Poplar Point Capital Management LLC
0.81%
The Vanguard Group, Inc.
0.07%
Geode Capital Management, L.L.C.
0.04%
State Street Investment Management (US)
0.02%
Apollon Wealth Management, LLC
0.02%
其他
99.04%
股东类型
持股股东
占比
Hedge Fund
0.81%
Investment Advisor
0.10%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.01%
其他
99.01%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
38
1.37M
22.81%
-82.54K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
2023Q2
47
9.53K
10.53%
-5.30K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Poplar Point Capital Management LLC
1.02M
16.99%
--
--
Sep 03, 2025
The Vanguard Group, Inc.
270.00
0%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
33.82K
0.56%
-1.17K
-3.35%
Jun 30, 2025
Tower Research Capital LLC
5.45K
0.09%
-6.00
-0.11%
Jun 30, 2025
Freiman (Paul Edward)
935.00
0.02%
+763.00
+443.60%
Sep 22, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
公告日期
类型
比率
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
常见问题
NovaBay Pharmaceuticals Inc的前五大股东是谁？
NovaBay Pharmaceuticals Inc 的前五大股东如下：
Poplar Point Capital Management LLC持有股份：1.02M，占总股份比例：16.99%。
The Vanguard Group, Inc.持有股份：270.00，占总股份比例：0.00%。
Geode Capital Management, L.L.C.持有股份：33.82K，占总股份比例：0.56%。
Tower Research Capital LLC持有股份：5.45K，占总股份比例：0.09%。
Freiman (Paul Edward)持有股份：935.00，占总股份比例：0.02%。
Poplar Point Capital Management LLC持有股份：1.02M，占总股份比例：16.99%。
The Vanguard Group, Inc.持有股份：270.00，占总股份比例：0.00%。
Geode Capital Management, L.L.C.持有股份：33.82K，占总股份比例：0.56%。
Tower Research Capital LLC持有股份：5.45K，占总股份比例：0.09%。
Freiman (Paul Edward)持有股份：935.00，占总股份比例：0.02%。
NovaBay Pharmaceuticals Inc的前三大股东类型是什么？
NovaBay Pharmaceuticals Inc 的前三大股东类型分别是：
Poplar Point Capital Management LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Poplar Point Capital Management LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
有多少机构持有NovaBay Pharmaceuticals Inc(NBY)的股份？
截至2025Q3，共有38家机构持有NovaBay Pharmaceuticals Inc的股份，合计持有的股份价值约为1.37M，占公司总股份的22.81%。与2025Q2相比，机构持股有所增加，增幅为-1.70%。
哪个业务部门对NovaBay Pharmaceuticals Inc的收入贡献最大？
在FY2024，Avenova业务部门对NovaBay Pharmaceuticals Inc的收入贡献最大，创收8.67M，占总收入的88.67%。
